Lineagen Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 125

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $7.14M

Lineagen General Information

Description

Developer of a genetic testing technology designed for children with neurodevelopmental disorders. The company's technology uses chromosomal microarray (CMA) testing technology, which can detect hundreds of genetic conditions and is recommended as the first-tier test for global developmental delay according to nationally accepted guidelines, enabling physicians to personalize medical management for individuals with developmental delay and an autism spectrum disorder.

Contact Information

Website
www.lineagen.com
Formerly Known As
GenData Research, Respiris, Lineagen Research
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Outcome Management (Healthcare)
Acquirer
Bionano
Corporate Office
  • 2677 East Parleys Way
  • Salt Lake City, UT 84109
  • United States
+1 (801) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lineagen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 21-Aug-2020 $7.14M 000.00 00.000 Completed Generating Revenue
14. Debt - PPP 13-Apr-2020 00.00 000.00 Completed
13. Debt - General 09-Oct-2019 000 000.00 Completed Generating Revenue
12. Later Stage VC 23-May-2019 00.00 000.00 Completed Generating Revenue
11. Later Stage VC (Series C1) 25-Jan-2017 00.000 000.00 000.00 Completed Generating Revenue
10. Later Stage VC (Series C1) 09-Jan-2015 000.00 000.00 000.00 Completed Generating Revenue
9. Later Stage VC (Series C) 22-Nov-2013 00.000 000.00 0000 Completed Generating Revenue
8. Later Stage VC (Series B) 24-Apr-2013 000.00 0000 000.00 Completed Generating Revenue
7. Grant 15-Dec-2011 $622K $24.8M Completed Generating Revenue
6. Early Stage VC (Series B) 04-Jan-2011 $5M $24.8M Completed Generating Revenue
To view Lineagen’s complete valuation and funding history, request access »

Lineagen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C1 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 00,000,000 00.000000 00 00 00 00 00 00.000
Series A 1,000 $0.001000 8% $1 $1 1x $1 0%
To view Lineagen’s complete cap table history, request access »

Lineagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a genetic testing technology designed for children with neurodevelopmental disorders. The company's technol
Other Healthcare Technology Systems
Salt Lake City, UT
125 As of 2023
000.00
00.000 0000-00-00
000000&0 000.00

000000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000 000000000
Sunnyvale, CA
0000 As of 0000
000.00
0000000000

000 00

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000000000000 000000
Alpharetta, GA
000 As of 0000
000.00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lineagen Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cepheid Formerly VC-backed Sunnyvale, CA 0000 000.00 0000000000
CSI Laboratories Formerly PE-Backed Alpharetta, GA 000 000000&0
Biocept Formerly VC-backed San Diego, CA 00 00000 000000000000 00000
Advanced Cell Diagnostics Formerly VC-backed Minneapolis, MN 000 000.00 000000&0 000.00
Ambry Genetics Corporate Backed or Acquired Aliso Viejo, CA 000 000000&0
You’re viewing 5 of 7 competitors. Get the full list »

Lineagen Patents

  • 77

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 13

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Lineagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190247326-A1 Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof Inactive 20-Sep-2016 000000000
US-20210212960-A1 Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof Inactive 20-Sep-2016 000000000
US-20170037475-A1 Genetic markers associated with asd and other childhood developmental delay disorders Inactive 09-Apr-2014 0000000000
CA-2945130-A1 Genetic markers associated with chromosomal deletion and duplication syndromes Inactive 09-Apr-2014 0000000000
AU-2015243449-A1 Genetic markers associated with chromosomal deletion and duplication syndromes Inactive 09-Apr-2014 C12Q1/6883
To view Lineagen’s complete patent history, request access »

Lineagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lineagen Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Archipel Capital Venture Capital Minority 000 0000 000000 0
Hatteras Funds Fund of Funds Minority 000 0000 000000 0
HealthQuest Capital Growth/Expansion Minority 000 0000 000000 0
Kickstart Fund Venture Capital Minority 000 0000 000000 0
Mesa Capital Partners PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Lineagen FAQs

  • When was Lineagen founded?

    Lineagen was founded in 2006.

  • Who is the founder of Lineagen?

    Alex Lindell, Mark Leppert Ph.D, Michael Paul Ph.D, and Stephen Prescott MD are the founders of Lineagen.

  • Where is Lineagen headquartered?

    Lineagen is headquartered in Salt Lake City, UT.

  • What is the size of Lineagen?

    Lineagen has 125 total employees.

  • What industry is Lineagen in?

    Lineagen’s primary industry is Other Healthcare Technology Systems.

  • Is Lineagen a private or public company?

    Lineagen is a Private company.

  • What is the current valuation of Lineagen?

    The current valuation of Lineagen is 00.000.

  • What is Lineagen’s current revenue?

    The current revenue for Lineagen is 00000.

  • How much funding has Lineagen raised over time?

    Lineagen has raised $53.4M.

  • Who are Lineagen’s investors?

    Archipel Capital, Hatteras Funds, HealthQuest Capital, Kickstart Fund, and Mesa Capital Partners are 5 of 16 investors who have invested in Lineagen.

  • Who are Lineagen’s competitors?

    Cepheid, CSI Laboratories, Biocept, Advanced Cell Diagnostics, and Ambry Genetics are some of the 7 competitors of Lineagen.

  • When was Lineagen acquired?

    Lineagen was acquired on 21-Aug-2020.

  • Who acquired Lineagen?

    Lineagen was acquired by Bionano.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »